Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis. Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than...
Hoofdauteurs: | Mead, A, Gale, R, Kottaridis, P, Matsuda, S, Khwaja, A, Linch, D |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
2008
|
Gelijkaardige items
-
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
door: Mead, A, et al.
Gepubliceerd in: (2007) -
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
door: Gale, R, et al.
Gepubliceerd in: (2008) -
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
door: Knapper, S, et al.
Gepubliceerd in: (2017) -
FLT3, NPM1, DNMT3a and NRAS genes mutation in acute myeloid leukaemia in HUSM
door: Mat Yunus, Noraini
Gepubliceerd in: (2015) -
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
door: Puissant, Alexandre, et al.
Gepubliceerd in: (2017)